Contineum Therapeutics (CTNM) Equity Ratio (2023 - 2026)

Contineum Therapeutics' Equity Ratio history runs 4 years deep, the most recent figure standing at 0.96 for Q1 2026.

• In Q1 2026, Equity Ratio rose 2.66% year-over-year to 0.96; the TTM figure through Mar 2026 stood at 0.96 (up 2.66% YoY), while the FY2025 annual figure was 0.94, up 1.38% from the prior year.
• Equity Ratio was 0.96 for Q1 2026 at Contineum Therapeutics, up from 0.94 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.98 in Q2 2024 to a low of 0.61 in Q1 2024.
• Historically, Equity Ratio has averaged 0.65 across 4 years, with a median of 0.94 in 2025.
• The sharpest annual moves came in 2024 and 2025: Equity Ratio surged 278.6% in 2024, then dropped 4.63% in 2025.
• A 4-year view of Equity Ratio shows it stood at 0.52 in 2023, then soared by 278.6% to 0.93 in 2024, then climbed by 1.38% to 0.94 in 2025, then climbed by 1.41% to 0.96 in 2026.
• The last three Equity Ratio figures came in at 0.96 (Q1 2026), 0.94 (Q4 2025), and 0.95 (Q3 2025), per Business Quant data.